Previous Close | 273.15 |
1-Year Change | 55.5% |
6-Months Change | 84.57% |
3-Months Change | 73.54% |
Moving Avg (50d) | 259.44 |
Moving Avg (200d) | 191.14 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 34.3B |
Beta (3-Years) | 0.87 |
Revenue Growth (ttm) | 79.37% |
Net Profit Margin (ttm) | -29.58% |
Return On Assets (ttm) | -13.28% |
EPS (ttm) | -4.14 |
PE Ratio (ttm) | -65.98 |
Dividend Yield | % |
Asset Description: | Alnylam Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2024-08-28 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
267.687 | 259.492 | 254.029 | 245.835 | 232.177 | 218.52 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.